CSX said it expects revenue to fall as much as 2% in 2019, well below a previous forecast of an increase of 1% to 2%.Marketsread more
Challenging conditions in the U.S. housing market, along with tighter currency controls by the Chinese government, cause a stunning drop in foreign demand for American homes.Real Estateread more
The growth in net interest income, a main engine of the industry's profit, looks to slow to a halt in the back half of this year.Banksread more
Amazon also said that on Monday and Tuesday it sold more Amazon devices — like the Echo Dot, the Fire TV Stick and Alexa Voice Remote — over a two-day period than it ever has...Retailread more
The news comes after eBay announced a strategic portfolio review on March 1.The Faber Reportread more
If the S&P 500 climbs another 4%, it will have doubled the peak reached in the previous bull market, Michael Santoli notes.Trading Nationread more
Ascending triangle patterns have been appearing across the stock market, and they tend to be precursors to higher prices, says Miller Tabak's Matt Maley.Trading Nationread more
Netflix reports earnings Wednesday as it loses licensed shows to rivals launching their own streaming services.Technologyread more
Hedge fund manager Kyle Bass reportedly thinks that U.S. interest rates will plummet toward zero in 2020 as the economy heads for recession.Hedge Fundsread more
Shares of beauty and wellness products company Nu Skin tanked on Wednesday after the company said China's crackdown on health products is weighing on sales.Investingread more
Buying stocks when they are this expensive has historically led to lower returns, data compiled by Ned Davis Research shows.Marketsread more
Zoetis shares rose 3 percent on Wednesday after the global animal-health company beat the Street's expectations and raised its outlook.
The New Jersey–based company reported second-quarter earnings of 48 cents per share on revenue of $1.2 billion, which beat estimates of $1.17 billion, according to Thomson Reuters.
Zoetis raised its guidance for fiscal year 2016 at $1.52 to $1.63 earnings per share and forecast its revenue to be in between $4.8 billion and $4.9 billion, the company said in a Wednesday release.
The company, which researches and creates medicine for pets and livestock, attributed its positive outlook to the growth of the cattle business, sales and strong operational revenues.
"We also continue to reap the benefits of a productive, world-class R&D organization focused on new discoveries like APOQUEL and SIMPARICA, as well as lifecycle innovations across our approximately 300 product lines. Our investments in internal R&D and external business development opportunities have us well-positioned as the world leader in animal health today and into the future," said Zoetis CEO Juan Ramon Alaix.
Zoetis shares closed at $51.21 on Wednesday. The stock has gained nearly 7 percent since the beginning of the year.